ACIX.F Stock Overview
A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Acarix AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.029 |
| 52 Week High | SEK 0.07 |
| 52 Week Low | SEK 0.014 |
| Beta | 1.48 |
| 11 Month Change | -5.26% |
| 3 Month Change | -4.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACIX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.4% | 0.9% | 2.2% |
| 1Y | n/a | 21.9% | 32.6% |
Return vs Industry: Insufficient data to determine how ACIX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ACIX.F performed against the US Market.
Price Volatility
| ACIX.F volatility | |
|---|---|
| ACIX.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACIX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ACIX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 14 | Aamir Mahmood | www.acarix.com |
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.
Acarix AB (publ) Fundamentals Summary
| ACIX.F fundamental statistics | |
|---|---|
| Market cap | US$29.12m |
| Earnings (TTM) | -US$6.56m |
| Revenue (TTM) | US$515.39k |
56.5x
P/S Ratio-4.4x
P/E RatioIs ACIX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACIX.F income statement (TTM) | |
|---|---|
| Revenue | SEK 5.68m |
| Cost of Revenue | SEK 550.00k |
| Gross Profit | SEK 5.13m |
| Other Expenses | SEK 77.36m |
| Earnings | -SEK 72.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.068 |
| Gross Margin | 90.31% |
| Net Profit Margin | -1,272.33% |
| Debt/Equity Ratio | 0% |
How did ACIX.F perform over the long term?
See historical performance and comparison